Logo image of NXL

NEXALIN TECHNOLOGY INC (NXL) Stock Fundamental Analysis

NASDAQ:NXL - Nasdaq - US65345B2016 - Common Stock - Currency: USD

1.02  +0.03 (+2.67%)

Premarket: 0.98 -0.04 (-3.92%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NXL. NXL was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While NXL seems to be doing ok healthwise, there are quite some concerns on its profitability. NXL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NXL had negative earnings in the past year.
In the past year NXL has reported a negative cash flow from operations.
NXL had negative earnings in each of the past 5 years.
NXL had a negative operating cash flow in each of the past 5 years.
NXL Yearly Net Income VS EBIT VS OCF VS FCFNXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

Looking at the Return On Assets, with a value of -294.97%, NXL is doing worse than 97.33% of the companies in the same industry.
The Return On Equity of NXL (-367.87%) is worse than 86.10% of its industry peers.
Industry RankSector Rank
ROA -294.97%
ROE -367.87%
ROIC N/A
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NXL Yearly ROA, ROE, ROICNXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 68.78%, NXL is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
NXL's Gross Margin has improved in the last couple of years.
NXL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
NXL Yearly Profit, Operating, Gross MarginsNXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

NXL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NXL has more shares outstanding
The number of shares outstanding for NXL has been increased compared to 5 years ago.
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NXL Yearly Shares OutstandingNXL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NXL Yearly Total Debt VS Total AssetsNXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -32.27, we must say that NXL is in the distress zone and has some risk of bankruptcy.
NXL has a worse Altman-Z score (-32.27) than 90.91% of its industry peers.
NXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.27
ROIC/WACCN/A
WACC8.86%
NXL Yearly LT Debt VS Equity VS FCFNXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

A Current Ratio of 4.56 indicates that NXL has no problem at all paying its short term obligations.
NXL has a Current ratio of 4.56. This is in the better half of the industry: NXL outperforms 72.19% of its industry peers.
NXL has a Quick Ratio of 4.25. This indicates that NXL is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.25, NXL is doing good in the industry, outperforming 75.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.56
Quick Ratio 4.25
NXL Yearly Current Assets VS Current LiabilitesNXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for NXL have decreased strongly by -22.64% in the last year.
The Revenue for NXL has decreased by -17.51% in the past year. This is quite bad
The Revenue has been decreasing by -4.05% on average over the past years.
EPS 1Y (TTM)-22.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.71%
Revenue 1Y (TTM)-17.51%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%-47.9%

3.2 Future

NXL is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.36% yearly.
NXL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 175.34% yearly.
EPS Next Y3.28%
EPS Next 2Y6.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year74.42%
Revenue Next 2Y175.34%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NXL Yearly Revenue VS EstimatesNXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200K 400K 600K 800K 1M
NXL Yearly EPS VS EstimatesNXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NXL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NXL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXL Price Earnings VS Forward Price EarningsNXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXL Per share dataNXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.36%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NXL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXALIN TECHNOLOGY INC

NASDAQ:NXL (8/5/2025, 8:00:02 PM)

Premarket: 0.98 -0.04 (-3.92%)

1.02

+0.03 (+2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/dmh
Earnings (Next)N/A N/A
Inst Owners2.3%
Inst Owner Change-15.35%
Ins Owners15.16%
Ins Owner Change0.08%
Market Cap17.77M
Analysts80
Price Target5.1 (400%)
Short Float %0.46%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-89.77%
Min EPS beat(2)-131.02%
Max EPS beat(2)-48.51%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.55%
Min Revenue beat(2)-10.89%
Max Revenue beat(2)15.98%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-40%
EPS NY rev (1m)-7.27%
EPS NY rev (3m)-7.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 135.64
P/FCF N/A
P/OCF N/A
P/B 7.64
P/tB 8.68
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.01
BVpS0.13
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -294.97%
ROE -367.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.78%
FCFM N/A
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 219.77%
Cap/Sales 28.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.56
Quick Ratio 4.25
Altman-Z -32.27
F-Score2
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.71%
EPS Next Y3.28%
EPS Next 2Y6.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.51%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%-47.9%
Revenue Next Year74.42%
Revenue Next 2Y175.34%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-45.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.48%
OCF growth 3YN/A
OCF growth 5YN/A